Adjuvant chemotherapy for advanced endometrial cancer

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 5, 2014, Pages

  Galaal, Khadra ^a   Al Moundhri, Mansour ^b   Bryant, Andrew ^c   Lopes, Alberto D ^a   Lawrie, Theresa A ^d  

^a ROYAL CORNWALL HOSPITAL   (United Kingdom)

^b SULTAN QABOOS UNIVERSITY HOSPITAL   (Oman)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

^d ROYAL UNITED HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; PACLITAXEL;

ABDOMINAL HYSTERECTOMY; ADJUVANT CHEMORADIOTHERAPY; ADVANCED CANCER; ALOPECIA; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CYTOREDUCTIVE SURGERY; DEATH; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; ENDOMETRIUM CANCER; EXTERNAL BEAM RADIOTHERAPY; GASTROINTESTINAL TOXICITY; HEMATOLOGIC DISEASE; HUMAN; INTESTINE OBSTRUCTION; MULTIPLE CYCLE TREATMENT; NEUROLOGIC DISEASE; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; REVIEW; SALPINGOOOPHORECTOMY; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; WHOLE BODY RADIATION; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADVERSE EFFECTS; CHEMORADIOTHERAPY; DISEASE FREE SURVIVAL; ENDOMETRIAL NEOPLASMS; FEMALE; META ANALYSIS; MORTALITY; PATHOLOGY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMORADIOTHERAPY; CHEMOTHERAPY, ADJUVANT; CISPLATIN; DISEASE-FREE SURVIVAL; DOXORUBICIN; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; NEOPLASM STAGING; PACLITAXEL; RADIOTHERAPY, ADJUVANT; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84938102787     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD010681.pub2     Document Type: Review

References (41)

1. Bruner DW, Barsevick A, Tian C, Randall M, Mannel R, Cohn DE, et al. Randomized trial results of quality of life comparing whole abdominal irradiation and combination chemotherapy in advanced endometrial carcinoma: A Gynecologic Oncology Group study. Quality of Life Research 2007;16(1):89-100.
2. Randall ME, Filiaci VL, Muss H, Spirtos NM, Mannel RS, Fowler J, et al. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. Journal of Clinical Oncology 2006;24(1):36-44.
3. Tewari KS, Filiaci VL, Spirtos NM, Mannel RS, Thigpen JT, Cibull ML, et al. Association of number of positive nodes and cervical stroma invasion with outcome of advanced endometrial cancer treated with chemotherapy or whole abdominal irradiation: a Gynecologic Oncology Group study. Gynecologic Oncology 2012;125(1):87-93.
4. Homesley HD, Filiaci V, Gibbons SK, Long HJ, Cella D, Spirtos NM, et al. A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: A Gynecologic Oncology Group study. Gynecologic Oncology 2009;112(3):543-52.
5. Maggi R, Lissoni A, Spina F, Melpignano M, Zola P, Favalli G, et al. Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial. British Journal of Cancer 2006;95(3):266-71.
6. Susumu N, Sagae S, Udagawa Y, Niwa K, Kuramoto H, Satoh S, et al. Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study. Gynecologic Oncology 2008;108(1):226-33.
7. Aapro MS, van Wijk FH, Bolis G, Chevallier B, van der Burg ME, Poveda A, et al. Doxurubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group. Annals of Oncology 2003;14(3):441-8.
8. Fleming GF, Filiaci VL, Bentley RC, Herzog T, Sorosky J, Vaccarello L, et al. Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study. Annals of Oncology 2004;15(8):1173-8.
9. Fleming GF, Brunetto VL, Cella D, Look KY, Reid GC, Munkarah AR, et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. Journal of Clinical Oncology 2004;22(11):2159-66.
10. Gallion HH, Brunetto VL, Cibull M, Lentz SS, Reid G, Soper JT, et al. Randomized phase III trial of standard timed doxorubicin plus cisplatin versus circadian timed doxorubicin plus cisplatin in stage III and IV or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. Journal of Clinical Oncology 2003;21(20):3808-13.
11. Hogberg T, Rosenberg P, Kristensen G, de Oliveira CF, de Pont Christensen R, Sorbe B, et al. A randomized phase III study on adjuvant treatment with radiation +/- chemotherapy in early-stage high-risk endometrial cancer (NSGO-EC-9501/EORTC55991) [Abstract]. Journal of Clinical Oncology. Abstracts of the 43rd Annual Meeting of the American Society of Clinical Oncology 2007;25(18 Suppl):Abstract 5503.
12. Hogberg T, Signorelli M, de Oliveira CF, Fossati R, Lissoni AA, Sorbe B, et al. Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer--results from two randomised studies. European Journal of Cancer 2010;46(13):2422-31.
13. Kuoppala T, Mäenpää J, Tomas E, Puistola U, Salmi T, Grenman S, et al. Surgically staged high-risk endometrial cancer: randomized study of adjuvant radiotherapy alone vs. sequential chemo-radiotherapy. Gynecologic Oncology 2008;110(2):190-5.
14. Mustea A, Koensgen D, Belau A, Sehouli J, Lichtenegger W, Schneidewind L, et al. Adjuvant sequential chemoradiation therapy in high-risk endometrial cancer: results of a prospective, multicenter phase-II study of the NOGGO (North-Eastern German Society of Gynaecological Oncology). Cancer Chemotherapy and Pharmacology 2013;72(5):975-83.
15. Nomura H, Aoki D, Takahashi F, Katsumata N, Watanabe Y, Konishi I, et al. Randomized phase II study comparing docetaxel plus cisplatin, docetaxel plus carboplatin, and paclitaxel plus carboplatin in patients with advanced or recurrent endometrial carcinoma: a Japanese Gynecologic Oncology Group study (JGOG2041). Annals of Oncology 2011;22(3):636-42.
16. Wolfson AH, Brady MF, Rocereto T, Mannel RS, Lee Y-C, Futoran RJ, et al. A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus. Gynecologic Oncology 2007;107(2):177-185.
17. Gynecologic Oncology Group. Carboplatin and paclitaxel with or without cisplatin and radiation therapy in treating patients with stage I, stage II, stage III, or stage IVA endometrial cancer. http://www.controlled-trials.com/mrct/trial/587551/endometrial+cancer (accessed 11 November 2013).
18. PORTEC-3 collaborators. Chemotherapy and radiation therapy compared with radiation therapy alone in treating patients with high-risk stage I, stage II, or stage III endometrial cancer. http://www.controlled-trials.com/mrct/trial/386235/PORTEC-3 2012.
19. Barlin JN, Puri I, Bristow RE. Cytoreductive surgery for advanced or recurrent endometrial cancer: a meta-analysis. Gynecologic Oncology 2010;118(1):14-8.
20. Berek JS, Hacker NF. Berek and Hacker's Gynecologic Oncology. 5th Edition. Lippincott Williams & Wilkins, 2010.
21. Colombo N, Preti E, Landoni F, Carinelli S, Colombo A, Marini C, et al. Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 2011;22(Suppl 6):vi35-39.
22. Creasman WT, Odicino F, Mausinneuve P, Quinn MA, Beller U, Benedet JL, et al. Carcinoma of the corpus uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. International Journal of Gynaecology and Obstetrics 2006;95(Suppl 1):S105-43.
23. Common terminology criteria for adverse events v3.0 (CTCAE). http://ctep.cancer.gov/forms/CTCAEv3.pdf 2006.
24. Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In: Egger M, Davey Smith G, Altman DG, editor(s). Systematic Reviews in Health Care: Meta-Analysis in Context. 2nd Edition. London: BMJ Publication Group, 2001.
25. Dubinsky TJ. Value of sonography in the diagnosis of abnormal vaginal bleeding. Journal of Clinical Ultrasound 2004;32(7):348-53.
26. Thomson Reuters. ENDNOTE X7.0.2. Thomson Reuters, 2013.
27. Evans T, Sany O, Pearmain P, Ganesan R, Blann A, Sundar S. Differential trends in the rising incidence of endometrial cancer by type: data from a UK population-based registry from 1994 to 2006. British Journal of Cancer 2011;104(9):1505-10.
28. Galaal K, Al Moundhri M, Bryant A, Lopes AD. Surgery and chemotherapy with or without radiotherapy for disseminated advanced endometrial cancer. Cochrane Database of Systematic Reviews 2013, Issue 8. [DOI: 10.1002/14651858.CD010681]
29. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60.
30. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
31. Humber CE, Tierney JF, Symonds RP, Collingwood M, Kirwan J, Williams C, et al. Chemotherapy for advanced, recurrent or metastatic endometrial cancer: a systematic review of Cochrane Collaboration. Annals of Oncology 2007;18(3):409-20.
32. The International Agency for Research on Cancer. GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012. http://globocan.iarc.fr/Pages/fact_sheets_population.aspx 2013.
33. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA: A Cancer Journal for Clinicians 2008;58(2):71-96.
34. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA: A Cancer Journal for Clinicians 2011;61(2):69-90.
35. Johnson N, Bryant A, Miles T, Hogberg T, Cornes P. Adjuvant chemotherapy for endometrial cancer after hysterectomy. Cochrane Database of Systematic Reviews 2011, Issue 10. [DOI: 10.1002/14651858.CD003175.pub2]
36. Kokka F, Brockbank E, Oram D, Gallagher C, Bryant A. Hormonal therapy in advanced or recurrent endometrial cancer. Cochrane Database of Systematic Reviews 2010, Issue 12. [DOI: 10.1002/14651858.CD007926.pub2]
37. Martin-Hirsch PPL, Bryant A, Keep SL, Kitchener HC, Lilford R. Adjuvant progestagens for endometrial cancer. Cochrane Database of Systematic Reviews 2011, Issue 6. [DOI: 10.1002/14651858.CD001040.pub2]
38. McMeekin DS. Where is the future of endometrial cancer therapy?. Annals of Oncology 2009;20(11):1757-61.
39. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012.
40. Kosary CL. Chapter 15: Cancer of the corpus uteri. In: Gloeckler Ries LA, Young JL, Keel GE, Eisner MP, Lin YD, Horner M-J editor(s). Cancer survival among adults: US SEER program, 1988-2001. Patient and Tumor Characteristics. Bethesda, MD: National Cancer Institute, 2007:123-132.
41. Vale CL, Tierney J, Bull SJ, Symonds PR. Chemotherapy for advanced, recurrent or metastatic endometrial carcinoma. Cochrane Database of Systematic Reviews 2012, Issue 8. [DOI: 10.1002/14651858.CD003915.pub4]